{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:09Z","timestamp":1789510629803,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.clon.2020.07.008","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T16:41:45Z","timestamp":1595695305000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies"],"prefix":"10.1016","volume":"33","author":[{"given":"C.","family":"Franzese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clon.2020.07.008_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2020.07.008_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2020.07.008_bib3","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.clon.2020.07.008_bib4","doi-asserted-by":"crossref","first-page":"v118","DOI":"10.1093\/annonc\/mdj965","article-title":"Long-term survival results of a randomized trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer","volume":"17","author":"Roberts","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2020.07.008_bib5","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.07.008_bib6","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMc1704612","article-title":"Pembrolizumab for advanced urothelial carcinoma","volume":"376","author":"Liang","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2020.07.008_bib7","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.21873\/anticanres.11140","article-title":"Metastasectomy improves survival in patients with metastatic urothelial carcinoma","volume":"36","author":"Iwamoto","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clon.2020.07.008_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.radonc.2018.10.024","article-title":"Predictive factors for survival of oligometastatic colorectal cancer treated with stereotactic body radiation therapy","volume":"133","author":"Franzese","year":"2019","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clon.2020.07.008_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00066-019-01523-9","article-title":"Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis","volume":"196","author":"Nicosia","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"10.1016\/j.clon.2020.07.008_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737140.2016.1178577","article-title":"Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting?","volume":"16","author":"Drazer","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.clon.2020.07.008_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5301\/tj.5000701","article-title":"Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer","volume":"104","author":"Mazzola","year":"2018","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.clon.2020.07.008_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.clon.2020.07.008_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1634\/theoncologist.2012-0092","article-title":"Review and uses of stereotactic body radiation therapy for oligometastases","volume":"17","author":"Alongi","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2020.07.008_bib14","first-page":"100124","article-title":"Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience","volume":"19","author":"Francolini","year":"2019","journal-title":"Cancer Treat Res Commun"},{"issue":"3 Suppl","key":"10.1016\/j.clon.2020.07.008_bib15","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.clon.2020.07.008_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/iju.13773","article-title":"Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series","volume":"25","author":"Leonetti","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clon.2020.07.008_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.clgc.2017.04.007","article-title":"Consolidative radiotherapy in metastatic urothelial cancer","volume":"15","author":"Shah","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clon.2020.07.008_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.athoracsur.2011.03.097","article-title":"Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?","volume":"92","author":"Matsuguma","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clon.2020.07.008_bib19","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.clgc.2015.04.013","article-title":"Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clon.2020.07.008_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1510\/icvts.2010.236687","article-title":"Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma","volume":"11","author":"Kanzaki","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.clon.2020.07.008_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5090\/kjtcs.2012.45.4.242","article-title":"Result of surgical resection for pulmonary metastasis from urothelial carcinoma","volume":"45","author":"Han","year":"2012","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clon.2020.07.008_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0090-4295(82)90462-9","article-title":"Long-term results following thoracotomy for metastatic bladder cancer","volume":"20","author":"Cowles","year":"1982","journal-title":"Urology"},{"key":"10.1016\/j.clon.2020.07.008_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clgc.2014.06.003","article-title":"Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design","volume":"13","author":"Necchi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clon.2020.07.008_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/PPO.0000000000000210","article-title":"Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors","volume":"22","author":"Brooks","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.clon.2020.07.008_bib25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2020.07.008_bib26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2020.07.008_bib27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clon.2020.07.008_bib28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12094-018-02005-7","article-title":"Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer","volume":"21","author":"Desideri","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"10185","key":"10.1016\/j.clon.2020.07.008_bib29","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clon.2020.07.008_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655520302909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655520302909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:49:08Z","timestamp":1760543348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655520302909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0936655520302909"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2020.07.008","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2020.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}